BullFrog AI Holdings, Inc. announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company's proprietary AI-driven platform, bfLEAP??. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a genomics research and innovation institution.JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 USD | -4.70% | -7.49% | -12.88% |
1st Jan change | Capi. | |
---|---|---|
-12.88% | 22.3M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.46% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- BFRG Stock
- News Bullfrog AI Holdings, Inc.
- BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP? Platform